TITLE

Panacea to set up new R&D centre in Mumbai

PUB. DATE
June 2005
SOURCE
Chemical Business;Jun2005, Vol. 19 Issue 6, p79
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
Reports on the plan of New Delhi-based Panacea Biotec Ltd. to establish a drug research and development center in Mumbai, India. Features of the center; Significance of the facility to medical innovations, including drug delivery technologies; Background on the operations of the company.
ACCESSION #
17868016

 

Related Articles

  • Panacea sets up new oncology unit.  // BioSpectrum;May2012, Vol. 10 Issue 5, p64 

    The article reports that vaccine producer Panacea Biotec Ltd. has opened up a new oncology facility at Baddi, Himachal Pradesh, India.

  • Panacea Biotec to set up new plant.  // Chemical Business;Aug95, Vol. 9 Issue 1, p27 

    Reports on plans by the Panacea Biotec company to set up a pharmaceutical plant at Lalroo in India. What plant will manufacture; Estimated cost of project; Company's plans for export; Background on Panacea Biotec; Achievements by company; Statistics on sales turnover for 1995.

  • Panacea launches polio vaccine in Nigeria.  // BioSpectrum;Apr2012, Vol. 10 Issue 4, p69 

    The article reports on the launch of Polprotec, an enhanced potency, inactivated poliovirus vaccine, by Panacea Biotec Ltd. in Nigeria.

  • A closer look at R&D trends in drug sector needed. Coopman, Robert // Chain Drug Review;1/6/2014, Vol. 36 Issue 1, p81 

    The article reports on the minor therapeutic innovations in the pharmaceutical research and development (R&D).

  • Panacea Biotec sets its eyes on generics.  // BioSpectrum;Oct2012, Vol. 10 Issue 10, p10 

    The article reports on the strategic alliance by Panacea Biotec Ltd. with Osmotica Pharmaceutical Corp. for the commercialization, research, and development of drug delivery-based, high barrier to branded and generic pharmaceutical products in the U.S. and strategic markets around the world.

  • Panacea gets govt order worth $34 mn.  // BioSpectrum;Jan2013, Vol. 11 Issue 1, p12 

    The article reports on the order of the Indian government for the supply of Trivalent Oral Polio Vaccines (tOPV) from Panacea Biotec worth $34 million.

  • Making profits working on patients' expectations, a behavioral analysis of pharmaceutical clinical research. Ippoliti, Roberto // Journal of Bioeconomics;Oct2012, Vol. 14 Issue 3, p217 

    This paper presents a model that demonstrates how pharmaceutical companies can make profits from human experimentation by working on patients' expectations and physicians' inability to evaluate innovations in medical knowledge. In order to understand how profits can be made, it is important to...

  • COMMON RESOURCES IN OPEN INNOVATION MODEL AS THE COMPETITION DRIVING AGENTS. AK-ŻOŁĘDOWSKA, ELŻBIETA POHUL // Ekonomia i Prawo;2014, Vol. 13 Issue 4, p559 

    The hereby article is addressed to the problem of innovation in new, Academia rooted industries. The traditional models of innovation seem to fail, whilst R&D activity of companies is more and more risky, and expensive. An example of pharmaceutical industry is given here. Pharmaceutical (and...

  • IMI's European Lead Factory Latest in Open Innovation. Moran, Nuala // BioWorld International;2/13/2013, Vol. 18 Issue 7, p1 

    The article reports on the European Lead Factory project of the Innovative Medicines Initiative (IMI). It says that the project will involve seven pharmaceutical companies which will provide at least 300,000 compounds for open platform screening. It says that the €80 million will be...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics